• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Non-persistence and non-adherence to MTX therapy in patients with rheumatoid arthritis: a retrospective cohort study based on German RA patients
【24h】

Non-persistence and non-adherence to MTX therapy in patients with rheumatoid arthritis: a retrospective cohort study based on German RA patients

机译：类风湿关节炎患者的非持久性和非坚持性MTX疗法：一项基于德国RA患者的回顾性队列研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: This study aimed to assess the level of nonpersistence (NP) and nonadherence (NA) to methotrexate (MTX) therapy in German patients with rheumatoid arthritis (RA). Materials and methods: Based on German claims data, RA patients who received a MTX therapy (subgroup: treatment-naive patients) were analyzed. NP was defined as treatment gap >12?weeks. Regarding NA, it is the overall medication possession ratio (MPR) during an observational period of 12 or 24?months after therapy, and the MPR is calculated only for the periods of therapy continuation; NA was defined as MPR <80%. Results: A total of 7,146 RA patients who received at least one MTX prescription (subgroup: 1,211 treatment-naive patients) could be observed (mean age: 64.4?years, 73.6% female). Percentage of NP patients among MTX-naive patients after 6, 12 and 18?months was 16.7%, 34.0% and 36.7%, respectively. After MTX therapy discontinuation, 39.9% had restarted their MTX therapy, 13.8% had received another non-MTX synthetic disease-modifying antirheumatic drug (sDMARD), 8.1% had biological DMARD (bDMARD) and 49.2% had not received any DMARD prescription at all. Overall, 12- and 24-month MPRs for MTX therapy were 83.0% and 76.5% with a percentage of NA patients of 25.8% and 33.8%, respectively. During periods of general treatment continuation, the percentage of patients with an MPR <80% was 6.5%. Conclusion: NP to MTX treatment seems to be common in one-fourth of German patients with RA. An additional number of patients, at least 6.5%, are also affected by NA. A considerable percentage of RA patients who discontinued MTX therapy do not receive any follow-up DMARD therapy.
机译：目的：本研究旨在评估德国类风湿关节炎（RA）患者对甲氨蝶呤（MTX）治疗的不持久（NP）和不粘连（NA）水平。材料和方法：根据德国的索赔数据，对接受MTX治疗的RA患者（亚组：未经治疗的患者）进行了分析。 NP定义为治疗间隔＞ 12周。关于NA，它是治疗后12或24个月观察期内的总体药物拥有率（MPR），仅在治疗持续期间计算MPR; NA被定义为MPR <80％。结果：总共可以观察到7,146名接受了至少一种MTX处方的RA患者（亚组：1,211名未经治疗的患者）（平均年龄：64.4岁，女性73.6％）。在6、12和18个月的未接受MTX的患者中，NP患者的百分比分别为16.7％，34.0％和36.7％。停用MTX疗法后，有39.9％的人重新开始了MTX疗法，有13.8％的人接受了另一种非MTX合成的改变疾病的抗风湿药（sDMARD），8.1％的人有生物DMARD（bDMARD），49.2％的人根本没有接受任何DMARD处方。总体而言，MTX治疗的12个月和24个月MPR分别为83.0％和76.5％，其中NA患者的比例分别为25.8％和33.8％。在继续常规治疗期间，MPR <80％的患者百分比为6.5％。结论：NP到MTX的治疗似乎在四分之一的德国RA患者中很常见。另外，至少6.5％的患者也受到NA的影响。相当大比例的中断MTX治疗的RA患者未接受任何后续DMARD治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号